Societe Generale Reiterates “$43.00” Price Target for Pfizer (PFE)

Societe Generale set a $43.00 price target on Pfizer (NYSE:PFE) in a research report released on Thursday. The firm currently has a hold rating on the biopharmaceutical company’s stock.

A number of other research firms also recently issued reports on PFE. ValuEngine upgraded shares of Pfizer from a hold rating to a buy rating in a report on Tuesday, October 9th. Morningstar set a $46.00 price objective on shares of Pfizer and gave the company a neutral rating in a report on Tuesday, October 9th. Independent Research set a $48.00 price objective on shares of Pfizer and gave the company a neutral rating in a report on Thursday, October 4th. Barclays set a $40.00 target price on shares of Pfizer and gave the company a neutral rating in a research note on Friday, October 19th. Finally, Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the company a buy rating in a research note on Thursday, October 4th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $42.95.

NYSE PFE opened at $42.93 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16. Pfizer has a 12-month low of $33.20 and a 12-month high of $45.81. The company has a market capitalization of $255.56 billion, a PE ratio of 16.20, a price-to-earnings-growth ratio of 2.16 and a beta of 0.88.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.03. Pfizer had a net margin of 44.63% and a return on equity of 25.34%. The company had revenue of $13.30 billion for the quarter, compared to the consensus estimate of $13.53 billion. During the same period last year, the company earned $0.67 earnings per share. The firm’s revenue was up 1.0% compared to the same quarter last year. On average, analysts predict that Pfizer will post 3 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be paid a $0.34 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.36 annualized dividend and a dividend yield of 3.17%. Pfizer’s dividend payout ratio is presently 51.32%.

In related news, major shareholder Pfizer Inc acquired 55,556 shares of Pfizer stock in a transaction on Monday, October 15th. The stock was purchased at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the transaction, the insider now directly owns 21,976,484 shares in the company, valued at approximately $395,576,712. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction on Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at $2,979,552. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. Ballew Advisors Inc bought a new position in Pfizer during the first quarter worth $102,000. Fort L.P. bought a new position in Pfizer during the second quarter worth $121,000. W.G. Shaheen & Associates DBA Whitney & Co bought a new position in Pfizer during the first quarter worth $132,000. Braun Bostich & Associates Inc. bought a new position in Pfizer during the first quarter worth $139,000. Finally, Smart Portfolios LLC boosted its position in Pfizer by 43.9% during the second quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 1,200 shares during the period. 69.01% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

See Also: Understanding each part of a balance sheet

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply